Bulletin from Annual General Meeting of Diamyd Medical AB
The Annual General Meeting of Diamyd Medical AB (publ) was held on November 30, 2023.
The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2022/2023. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2022/2023.
Anders Essen-Möller, Erik Nerpin, Maria-Teresa Essen-Möller, Torbjörn Bäckström, Mark A. Atkinson and Karin Hehenberger were re-elected to the Board. Karin Rosén, M.D, PhD, was elected as a new member of the Board.
Anders Essen-Möller was elected as Chairman of the Board and Erik Nerpin was elected as Vice Chairman of the Board.
The Annual General Meeting approved the proposed remuneration to Board members, the Chairman of the Board and the Vice Chairman of the Board.
The Annual General Meeting resolved to re-elect the auditing company BDO until the end of the Annual General Meeting 2024. Principal auditor is the authorized public accountant Johan Pharmanson.
The Annual General Meeting resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting, to issue shares and/or warrants and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares and/or warrants issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs.
About Diamyd Medical
Diamyd Medical develops precision medicine therapies for Type 1 Diabetes. Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. DIAGNODE-3, a confirmatory Phase III trial is actively recruting patients with recent-onset Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where Diamyd® was administered directly into a lymph node in children and young adults with recently diagnosed Type 1 Diabetes. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.
Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com
Publication
The information was submitted for publication, through the agency of the contact person set out above, at 16.45 CET on November 30, 2023.
Tags: